At AstraZeneca, fewer drug projects bring big productivity jump

LONDON, Jan 19 (Reuters) - A focus on fewer diseases, together with cuts in laboratories and staff, has delivered a more than fourfold increase in research productivity at drugmaker AstraZeneca, based on one key measure of success.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.